Runners, cyclists and other fitness enthusiasts say weight-loss drugs give them a performance edge, despite potential risks.

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...